You are here

  • Home
  • Archive
  • Volume 78, Issue 11
  • Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response

Article metrics

Article menu
XML
Rheumatoid arthritis
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response

 

Online download statistics by month:

Online download statistics by month: July 2019 to March 2024

AbstractFullPdf
Jul 201914114333
Aug 201914271427907
Sep 201910761069426
Oct 201915291488600
Nov 201912311208733
Dec 2019690674333
Jan 2020729707380
Feb 2020742721407
Mar 2020596571311
Apr 2020533516434
May 2020450440327
Jun 2020436431278
Jul 2020386376210
Aug 2020465446213
Sep 2020423399261
Oct 2020568550312
Nov 2020606575350
Dec 2020404385229
Jan 2021455436230
Feb 2021514491350
Mar 2021549524322
Apr 2021389364228
May 2021406390228
Jun 2021383362209
Jul 2021278264208
Aug 2021283270184
Sep 2021370333228
Oct 2021401383203
Nov 2021361349219
Dec 2021254246134
Jan 2022276275150
Feb 2022350391157
Mar 2022398397218
Apr 2022383396199
May 2022391393165
Jun 2022308293105
Jul 2022268260123
Aug 2022295277133
Sep 2022393383135
Oct 2022302298165
Nov 2022395379162
Dec 2022310295140
Jan 2023292284127
Feb 2023350327131
Mar 2023377350143
Apr 2023322309128
May 2023343317129
Jun 2023338321122
Jul 2023341325101
Aug 2023332318149
Sep 2023347336144
Oct 2023511489128
Nov 2023606576135
Dec 202329327399
Jan 202420017678
Feb 202424923498
Mar 2024388385165
Total264332559513216